Insys Therapeutics (NASDAQ:INSY) Director Patrick Fourteau acquired 7,500 shares of the stock in a transaction dated Thursday, May 15th. The shares were purchased at an average cost of $22.77 per share, for a total transaction of $170,775.00. Following the completion of the acquisition, the director now directly owns 105,000 shares in the company, valued at approximately $2,390,850. Insys Therapeutics Inc. (NASDAQ:INSY) net profit margin is 40.60% and weekly performance is -42.51%. On last trading day company shares ended up $22.60. Analysts mean target price for the company is $62.00. Insys Therapeutics Inc. (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -45.10%.
Merrimack Pharmaceuticals (NASDAQ:MACK) Director Michael Porter purchased 10,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, May 8th. The shares were purchased at an average cost of $6.59 per share, for a total transaction of $65,900.00. Following the acquisition, the director now directly owns 520,865 shares in the company, valued at approximately $3,432,500. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) shares advanced 0.15% in last trading session and ended the day on $6.69. MACK return on assets is -80.10%.Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) quarterly performance is 36.25%.
Intrexon Corp (NYSE:XON) COO Krish Krishnan purchased 20,900 shares of Intrexon Corp stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $14.21 per share, for a total transaction of $296,989.00. Following the purchase, the chief operating officer now directly owns 20,900 shares in the company, valued at approximately $296,989. Intrexon Corp (NYSE:XON) shares moved up 4.06% in last trading session and was closed at $18.20, while trading in range of $16.55 – $18.29. Intrexon Corp (NYSE:XON) year to date (YTD) performance is -23.53%.
Durata Therapeutics (NASDAQ:DRTX) Director Schutter Richard De bought 15,000 shares of the company’s stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $15.57 per share, with a total value of $233,550.00. Following the completion of the purchase, the director now directly owns 15,000 shares of the company’s stock, valued at approximately $233,550. Durata Therapeutics Inc. (NASDAQ:DRTX) ended the last trading day at $16.31. Company weekly volatility is calculated as 4.83% and price to cash ratio as 7.27.Durata Therapeutics Inc. (NASDAQ:DRTX) showed a positive weekly performance of 14.86%.
Verastem (NASDAQ:VSTM) CEO Robert Forrester purchased 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 13th. The shares were purchased at an average price of $7.62 per share, for a total transaction of $7,620.00. Following the completion of the transaction, the chief executive officer now directly owns 239,320 shares of the company’s stock, valued at approximately $1,823,618. Verastem Inc. (NASDAQ:VSTM) weekly performance is 6.72%. On last trading day company shares ended up $7.62. Analysts mean target price for the company is $21.70. Verastem Inc. (NASDAQ:VSTM) distance from 50-day simple moving average (SMA50) is -25.45%.